

DAFTAR PUSTAKA

- Aberg, J.A., Lacy, C., Amstrong, L., Goldman, M., dan Lance, L.L., 2009. *Drug Information Handbook, 17th ed.* American Pharmacist Association.
- Aggarwal, M., Dass, J., & Mahapatra, M. (2020). Hemostatic abnormalities in COVID-19: an update. *Indian Journal of Hematology and Blood Transfusion*, 36, 616-626.
- Ahmed, R., Ganguli, P., Singh, N., Singh, S., Gupta, U. D., Jaiswal, Y. K., ... & Nair, V. (2019). Establishing reference ranges and normal values for coagulation screening in healthy Indian male volunteers enrolled for a longitudinal study. *Biomedical and Biotechnology Research Journal (BBRJ)*, 3(1), 22.
- Ahmed, R., Ganguli, P., Singh, N., Singh, S., Gupta, U., Jaiswal, Y., dkk., 2019. Establishing reference ranges and normal values for coagulation screening in healthy Indian male volunteers enrolled for a longitudinal study. *Biomedical and Biotechnology Research Journal (BBRJ)*, 3: 22.
- Araya, S., Mamo, M. A., Tsegay, Y. G., Atlaw, A., Aytnew, A., Hordofa, A., ... & Tamir, Z. (2021). Blood coagulation parameter abnormalities in hospitalized patients with confirmed COVID-19 in Ethiopia. *Plos one*, 16(6), e0252939.
- Ashorobi, D., Ameer, M. A., dan Fernandez, R. 2021. *Thrombosis*. StatPearls (internet). StatPearls publishing.
- ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators Lawler, P. R., Goligher, E. C., Berger, J. S., dkk. 2021. Therapeutic Anticoagulation with heparin in Noncritically Ill Patients with COVID-19. *the new England Journal of Medicine*, 385: 790-802.
- Becker, R. C. (2020). COVID-19 update: COVID-19-associated coagulopathy. *Journal of thrombosis and thrombolysis*, 50(1), 54-67.
- Billett, H.H., Reyes-Gil, M., Szymanski, J., Ikemura, K., Stahl, L.R., Lo, Y., dkk., 2020. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. *Thrombosis and Haemostasis*, 120: 1691–1699.

- Billet, 1990. *Clinical Methods: The History, Physical, and Laboratory Examinations*. 3rd edition. *Boston: Butterworths. Chapter 151*, 124.
- NHS, 2023. Erythrocytosis. *National Health Service*.
- Bounds, E. J., & Kok, S. J., 2021. D Dimer. *StatPearls*.
- Cardillo, G., Viggiano, G. V., Russo, V., Mangiacapra, S., Cavalli, A., Castaldo, G., ... & FondenoxavidStudy Group. (2021). Antithrombotic and anti-inflammatory effects of Fondaparinux and enoxaparin in hospitalized COVID-19 patients: the Fondenoxavid study. *Journal of blood medicine*, 69-75.
- Cevik, M., Kuppalli, K., Kindrachuk, J., & Peiris, M. (2020). Virology, transmission, and pathogenesis of SARS-CoV-2. *bmj*, 371.
- Costantino, G., Ceriani, E., Rusconi, A.M., Podda, G.M., Montano, N., Duca, P., dkk., 2012. Bleeding Risk during Treatment of Acute Thrombotic Events with Subcutaneous LMWH Compared to Intravenous Unfractionated heparin; A Systematic Review. *PLoS ONE*, 7: e44553.
- Cui, S., Chen, S., Li, X., Liu, S., dan Wang, F., 2020. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *Journal of Thrombosis and Haemostasis*, 0.1111/jth.14830.
- Demelo-Rodriguez, P., Farfán-Sedano, A.I., Pedrajas, J.M., Llamas, P., Sigüenza, P., Jaras, M.J., dkk., 2021. Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis. *Journal of Thrombosis and Haemostasis*, 19: 1981–1989.
- Di Gennaro, F., Pizzol, D., Marotta, C., Antunes, M., Racalbutto, V., Veronese, N., & Smith, L. (2020). Coronavirus diseases (COVID-19) current status and future perspectives: a narrative review. *International journal of environmental research and public health*, 17(8), 2690.
- Drago, F., Gozzo, L., Li, L., Stella, A., & Cosmi, B. (2020). Use of enoxaparin to counteract COVID-19 infection and reduce thromboembolic venous complications: a review of the current evidence. *Frontiers in pharmacology*, 11, 579886.
- Ganesh, B., Rajakumar, T., Malathi, M., Manikandan, N., Nagaraj, J., Santhakumar, A., ... & Malik, Y. S. (2021). Epidemiology and

- pathobiology of SARS-CoV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future perspectives. *Clinical epidemiology and global health*, 10, 100694.
- Geerts, W.H., Bergqvist, D., Pineo, G.F., Heit, J.A., Samama, C.M., Lassen, M.R., dkk., 2008. Prevention of venous thromboembolism: *American College of Chest*
- Gross, S., Jahn, C., Cushman, S., Baer, C., & Thum, T. (2020). SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications. *Journal of Molecular and Cellular Cardiology*, 144, 47-53.
- Hajra, A., Mathai, S.V., Ball, S., Bandyopadhyay, D., Veyseh, M., Chakraborty, S., dkk., 2020. Management of Thrombotic Complications in COVID-19: An Update. *Drugs*, 80: 1553–1562.
- Haqqani, O.P., Lafrati, M.D., dan Freedman, J.E., 2013. Chapter 7- Pharmacology of Antithrombotic Drugs 94–109.
- Harter, K., Levine, M., & Henderson, S. O. (2015). Anticoagulation drug therapy: a review. *Western Journal of Emergency Medicine*, 16(1), 11.
- Hidayati, S.N., 2022. Perbandingan Efektivitas dan Keamanan Penggunaan Antikoagulan Profilaksis Unfractionated Heparin dan Enoxaparin pada Pasien COVID-19, Universitas Gadjah Mada, Yogyakarta.
- Hirsh, J., Anand, S.S., Halperin, J.L., dan Fuster, V., 2001. Mechanism of Action and Pharmacology of Unfractionated Heparin. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 21: 1094–1096.
- Hunt, B. J. (2014). Bleeding and coagulopathies in critical care. *New England Journal of Medicine*, 370(9), 847-859.
- Iba, T., Levy, J. H., Levi, M., Connors, J. M., & Thachil, J. (2020). Coagulopathy of coronavirus disease 2019. *Critical care medicine*.
- IDI. 2020. *Rekomendasi IDI Pemberian Antikoagulan Profilaksis Pada Pasien COVID-19 yang Dirawat di Rumah Sakit*. Jakarta
- Johnson, E. D., Schell, J. C., & Rodgers, G. M. (2019). The D-dimer assay. *American journal of hematology*, 94(7), 833-839.

- Jupalli A., Iqbal A.M., 2021. Enoxaparin. *StatPearls*.
- Jupalli, A., & Iqbal, A. M., (2021). enoxaparin. XPharm: The Comprehensive *Pharmacology Reference*, 1-4. <https://www.ncbi.nlm.nih.gov/books/NBK539865/>
- Kaatz, S., Ahmad, D., Spyropoulos, A.C., dan Schulman, S., 2015. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. *Journal of Thrombosis and Haemostasis*, 13: 2119–2126.
- Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., Arbous, M.S., Gommers, D.A.M.P.J., Kant, K.M., dkk., 2020. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thrombosis Research*, 191: 145–147.
- Kluge, S., Janssens, U., Welte, T., Weber-Carstens, S., Marx, G., dan Karagiannidis, C., 2020. German recommendations for critically ill patients with COVID-19. *Medizinische Klinik - Intensivmedizin und Notfallmedizin*, 115: 111–114.
- Lemeshow, S., Hosmer, D.W., Klar, J., Lwanga, S.K., dan World Health Organization, 1990. Adequacy of Sample Size in Health Studies. *Wiley, Chichester*.
- Lemos, A.C.B., do Espírito Santo, D.A., Salvetti, M.C., Gilio, R.N., Agra, L.B., PazinFilho, A., dkk., 2020. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). *Thrombosis Research*, 196: 359–366.
- Li, H., Liu, S. M., Yu, X. H., Tang, S. L., & Tang, C. K. (2020). Coronavirus disease 2019 (COVID-19): current status and future perspectives. *International journal of antimicrobial agents*, 55(5), 105951.
- Linkins, L. A., & Takach Lapner, S. (2017). Review of D-dimer testing: good, bad, and ugly. *International Journal of Laboratory Hematology*, 39, 98-103.
- Liu, Z., Ji, S., Sheng, J., dan Wang, F., 2014. Pharmacological effects and clinical applications of ultra low molecular weight heparins. *Drug Discoveries & Therapeutics*, 8: 1–10.

- Luo, H.-C., You, C.-Y., Lu, S.-W., dan Fu, Y.-Q., 2021. Characteristics of coagulation alteration in patients with COVID-19. *Annals of Hematology*, 100: 45–52.
- Ma, M., Liang, S., Zhu, J., Dai, M., Jia, Z., Huang, He., He, Yong., 2022. The Efficacy and Safety of Bivalirudin Versus Heparin in the Anticoagulation Therapy of Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis. *Frontiers in Pharmacology*. 13: 3.
- Madoiwa, S., 2015. Recent advances in disseminated intravascular coagulation: endothelial cells and fibrinolysis in sepsis-induced DIC. *Journal of Intensive Care*, 3: 8.
- Mai, F., Pinto, R.D., dan Ferri, C., 2020. COVID-19 and cardiovascular diseases. *Journal of Cardiology*, 76: 453–458.
- Mattioli, M., Benfaremo, D., Mancini, M., Mucci, L., Mainquà, P., Polenta, A., dkk., 2021. Safety of intermediate dose of low molecular weight heparin in COVID-19 patients. *Journal of Thrombosis and Thrombolysis*, 51: 286–292.
- Musoke, N., Lo, K. B., Albano J., Peterson E., Bhargav R., Gul F., DeJoy 3rd R., Salacup, G., Pelayo, J., 2020. Anticoagulation and Bleeding Risk in Patients with COVID-19. *Thrombosis Research* 196: 227-229.
- Musyrifah, S.A. 2023. Perbandingan Efektivitas Dan Keamanan Penggunaan Antikoagulan Fondaparinux, Enoxaparin Dan Heparin Pada Pasien COVID-19 dengan Hypercoagulable State di RSUD Kabupaten Kediri. *Universitas Gadjah Mada*. 20-105.
- Oudkerk, M., Büller, H.R., Kuijpers, D., van Es, N., Oudkerk, S.F., McLoud, T., dkk., 2020. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands. *Radiology*, 297: E216–E222.
- Parasher, A. (2021). COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. *Postgraduate medical journal*, 97(1147), 312-320.
- Pawlowski, C., Venkatakrishnan, A. J., Kirkup, C., Berner, G., Puranik, A., O'Horo, J. C., ... & Soundararajan, V. (2021). enoxaparin is

associated with lower rates of mortality than unfractionated heparin in hospitalized COVID-19 patients. *EClinicalMedicine*, 33, 100774.

PDPI, PERKI, PAPDI, PERDATIN, dan IDAI. 2020. *Pedoman Tata Laksana COVID-19 edisi 3, 3rd ed.* Jakarta

Perhimpunan Dokter Paru Indonesia, Perhimpunan Dokter Spesialis Kardiovaskular Indonesia, Perhimpunan Dokter Spesialis Penyakit Dalam, Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia, dan Ikatan Dokter Anak Indonesia, 2022. *Buku Pedoman Tatalaksana COVID-19 Edisi 4 (Januari 2022), 4th ed.* Jakarta.

Pesavento, R., Ceccato, D., Pasquetto, G., Monticelli, J., Leone, L., Frigo, A., dkk., 2020. The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with COVID-19: the Padua province experience. *Journal of Thrombosis and Haemostasis*, 10.1111/jth.15022.

Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*, 133: 381S-453S.

Poudel, R., Daniels, L.B., DeFilippis, A.P., Hamburg, N.M., Khan, Y., Keith, R.J., dkk., 2022. Smoking is associated with increased risk of cardiovascular events, disease severity, and mortality among patients hospitalized for SARS-CoV-2 infections. *PLOS ONE*, 17: e0270763.

Rauf, A., Abu-Izneid, T., Olatunde, A., Ahmed Khalil, A., Alhumaydhi, F. A., Tufail, T., . & Rengasamy, K. R. (2020). COVID-19 pandemic: epidemiology, etiology, conventional and non-conventional therapies. *International journal of environmental research and public health*, 17(21), 8155.

Rieder M, Gauchel N, Kaier K, et al. Pre-medication with oral anticoagulants is associated with better outcomes in a large multinational COVID-19 cohort with cardiovascular comorbidities. 2022. *Clin Res Cardiol*, 111(3):322-332.

Rostami, M., & Mansouritorghabeh, H. (2020). D-dimer level in COVID-19 infection: a systematic review. *Expert review of hematology*, 13(11), 1265-1275.

- Satuan Tugas Penanganan COVID-19, W.R.P.C-19, 2021. 'Peta Sebaran', *COVID19.go.id*. URL: <https://COVID19.go.id/peta-sebaran>.
- Shah, S., Shah, K., Patel, S. B., Patel, F. S., Osman, M., Velagapudi, P., ... & Garg, J. (2020). Elevated D-dimer levels are associated with increased risk of mortality in coronavirus disease 2019: a systematic review and meta-analysis. *Cardiology in review*, 28(6), 295-302.
- Stoneham, S.M., Milne, K.M., Nuttall, E., Frew, G.H., Sturrock, B.R., Sivaloganathan, H., dkk., 2020. Thrombotic risk in COVID-19: a case series and case-control study. *Clinical Medicine (London, England)*, 20: e76–e81.
- Tabiban, S., Rahbar, K., Ghadrdoost, B., Zahed, N., Falaknazi, K., dan Piraste, H., 2017. Comparison of enoxaparin Sodium and Standard heparin for Hemodialysis Anticoagulation. *Nephro-Urology Monthly*, InPress
- Tang, N., Bai, H., Chen, X., Gong, J., Li, D., & Sun, Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *Journal of thrombosis and haemostasis*, 18(5), 1094-1099.
- Terra, P.O.C., Donadel, C.D., Oliveira, L.C., Meneguetti, M.G., Auxiliadora-Martins, M., Calado, R.T., dkk., 2022. Neutrophil-to-lymphocyte ratio and D-dimer are biomarkers of death risk in severe COVID-19: A retrospective observational study. *Health Science Reports*, 5: e514.
- Ullah, W., Saeed, R., Sarwar, U., Patel, R., dan Fischman, D.L., 2020. COVID-19 Complicated by Acute Pulmonary Embolism and Right-Sided Heart Failure. *JACC: Case Reports*, 2: 1379–1382.
- Veeranki, S.P., Xiao, Z., Levorsen, A., Sinha, M., dan Shah, B.R., 2021. Real- World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of enoxaparin versus Unfractionated heparin in 376,858 Medically Ill Hospitalized US Patients. *American Journal of Cardiovascular Drugs*, 21: 443–452.
- Wang, C., Wang, Z., Wang, G., Lau, J. Y. N., Zhang, K., & Li, W. (2021). COVID-19 in early 2021: current status and looking forward. *Signal Transduction and Targeted Therapy*, 6(1), 114.

- Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020). Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. *Jama*, *324*(8), 782-793.
- Willim, H. A., Hardigaloeh, A. T., Supit, A. I., & Handriyani, H. (2020). Koagulopati pada coronavirus disease-2019 (COVID-19): tinjauan pustaka. *Intisari Sains Medis*, *11*(3), 1130-1137.
- World Health Organization. (2021). COVID-19 weekly epidemiological update, 9 March 2021.
- Yao, Y., Cao, J., Wang, Q., Shi, Q., Liu, K., Luo, Z., ... & Hu, B. (2020). D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. *Journal of intensive care*, *8*, 1-11.
- Yorike, D., Kurniawan, M.R., dan Syafaat, M., 2022. Analysis of D-dimer Level and Prothombin Time (PT) Activated Prothombin Thromboplastin (APTT) on Heparin Administration to COVID-19 Patients. *Indonesian Journal of Medical Laboratory Science and Technology*, *4*: 91–98.
- YORMAZ, B., ERGÜN, D., TÜLEK, B., ERGÜN, R., ARSLAN, U., dan KANAT, F., 2021. Impact of low molecular weight heparin administration on the clinical course of the COVID-19 disease. *Turkish Journal of Medical Sciences*, *51*: 28–38.